Neumora shares surge 13.39% premarket after RBC upgrades rating to Outperform and raises price target to $7.

Neumora Therapeutics (NASDAQ:NMRA) surged 13.39% in premarket trading following a series of upgrades and positive developments. RBC Capital upgraded the stock to Outperform from Sector Perform and raised its price target to $7 from $4, citing Neumora’s expansion beyond neurology into high-potential markets like obesity and cardiometabolic disease. The firm highlighted the company’s competitive NLRP3 inhibitor pipeline, with key data expected in 2026. Additionally, Guggenheim upgraded NMRA to Buy with a $14 price target, driven by promising preclinical results for NMRA-215, which achieved 19% weight loss as a monotherapy and 26% when combined with semaglutide. These upgrades, alongside the stock’s undervaluation and strategic pipeline advancements, including a Phase 1 trial for NMRA-898, fueled optimism ahead of 2026 data milestones.